ascopubs.org

Impact of 36 months of androgen-deprivation therapy (ADT) on physical function and quality of life (QOL) in men with nonmetastatic prostate cancer.

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate ...
ascopubs.org

Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study.

Value of early referral to improve fertility preservation outcomes in women with breast cancer. Background: ADT is used to treat almost 50% of current PC patients. Despite slowing disease progression ...